Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB

NCT02921919 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02921919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02921919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2016
Completion date
July 20, 2021
Enrollment
120 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

cancer